Pharmaceutically acceptable carrier for ophthalmic compositions

A composition and treatment composition technology, applied in the directions of pharmaceutical formulations, drug delivery, medical preparations containing active ingredients, etc., can solve problems such as limiting hormones, and achieve the effects of alleviating clinical symptoms, discomfort and irritation

Inactive Publication Date: 2008-08-27
NASCENT PHARMA
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Conservative medicine would indicate that local rather than systemic administration is desired, thus limiting the effect of the hormone on the target

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] A. Preparation of Compositions of the Invention

[0047] The following is a description of the filling, labeling and packaging procedures for preparing an ophthalmic drop bottle according to a preferred embodiment of the present invention. The bottles are inspected first, they must meet the following requirements: conform to the physical description in the vial package insert, have a certificate of inspection, and have a record of preparation. These vials were then released for manufacturing use.

[0048] Examine the pipette tips, they must meet the following requirements: conform to the physical description in the pipette tip instruction booklet, have inspection certificates, and have preparation records. These dropper tips are then released for manufacturing use.

[0049] Check the dropper caps, they must meet the following conditions: Fit the physical description in the dropper cap instruction sheet. These dropper caps were then released for manufacturing use.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A pharmaceutically acceptable carrier for ophthalmic compositions useful in treating or alleviating the symptoms of dry eye syndrome, elevated intra-ocular pressure, age-related maculopathy or age-related macular degeneration.

Description

field of invention [0001] The present invention relates generally to methods of treatment and therapeutic compositions in the field of ophthalmology, and more particularly, to artificial tear compositions by themselves or as active ingredients (especially for the treatment and / or prophylaxis of dry eye syndrome, ocular An ophthalmic pharmaceutical composition of a carrier for an ophthalmic clinical symptom and / or sign associated with increased internal pressure, age-related macular disease and age-related macular degeneration). Background of the invention [0002] In summary, dry eye syndrome is a tear film disorder that results in damage to the interpalpebral ocular surface due to tear deficiency or excessive tear evaporation and is associated with symptoms of ocular discomfort. (Lemp, M.A. Report of the National Eye Institute / Industry Workshop on Clinical Trias in Dry Eyes, The Contact Les Association of Ophthalmologists Journal, 21(4):221-231 (1995)). Findings show diffe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56
CPCA61K31/565A61K31/568A61K45/06A61K31/56A61K9/0048
Inventor C·德西杜米G·巴尼特M·科伊
Owner NASCENT PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap